Myriad Genetics, Inc. (MYGN)

Myriad Genetics' stock price has experienced significant fluctuations over the past six months. The stock saw a decline of 17.68% over the last six months and a 60.03% decrease over the past year. Key events impacting the stock include a revenue decline in Q1 2025 due to reduced coverage for GeneSight, an analyst downgrade, strong adjusted gross margin and adjusted EBITDA in Q2 2025 leading to raised guidance, securing a term loan from OrbiMed, and meeting Wall Street's revenue expectations in Q3 2025. There is contradictory information regarding the stock's return over the past six months, with one source indicating a positive return, while others indicate a decline.

Myriad Genetics' business experiences seasonal patterns in demand for its products and services. The company typically sees lower volumes in the first quarter of the year due to insurance deductible resets, and demand also tends to be lower during the summer months. Conversely, the fourth quarter often experiences increased volumes as patients reach their annual deductibles, leading to higher utilization of healthcare services, including genetic testing.

Myriad Genetics, Inc. is an American genetic testing and precision medicine company focused on discovering, developing, and marketing transformative molecular diagnostic tests. The company operates in the healthcare sector, specifically in the molecular diagnostics and biotechnology industry, aiming to provide insights for managing health and enabling better disease detection, treatment, and prevention through understanding the genetic basis of human disease. Myriad Genetics' major products include Prolaris, MyRisk Hereditary Cancer, Foresight Carrier Screen, SneakPeek, GeneSight, and Endopredict. The company also offers testing products and services to the pharmaceutical, biotechnology, and medical research industries, along with research and development and clinical services for patients.

Myriad Genetics, Inc. is headquartered in Salt Lake City, Utah, United States. The company generates revenue through a sales force of approximately 500 individuals across dedicated sales channels in the United States, Japan, Germany, and France. Additionally, Myriad Genetics serves other global accounts through indirect channels.

In the past year, Myriad Genetics has been covered by media for 39 events, with 22 related to company updates and 7 to partnerships. Notable events include a partnership with Zydus Lifesciences Limited, an alliance with Ferrimax, the launch of an integrated AI and genetic risk platform with Clairity and MagView, an expanded cancer care focus and new MyRisk panel launch, the addition of F8 and FXN genes to Foresight Universal Accessibility, a collaboration with SOPHiA GENETICS, and advancing MRD commercialization.

Myriad Genetics, Inc. has 450 institutional owners and shareholders holding a total of 106,885,929 shares. Major institutional owners include BlackRock, Inc., Vanguard Group Inc., iShares Core S&P Small-Cap ETF (IJR), State Street Corp., Millennium Management Llc., Glenview Capital Management, Llc., D. E. Shaw & Co., Inc., Morgan Stanley, Vanguard Total Stock Market Index Fund Investor Shares (VTSMX), and Jacobs Levy Equity Management, Inc.